抗病毒治疗降低轻度ALT升高慢性乙肝患者肝癌与肝硬化风险
这项回顾性多中心研究纳入3734例ALT<2×ULN的非肝硬化慢性乙肝患者,37.8%接受核苷(酸)类似物治疗。经IPTW和PSM平衡基线后,治疗组5年肝癌累积发生率0.9% vs 4.4%,肝硬化4.0% vs 8.9%,均显著降低;获益见于ALT 1–2×ULN亚组,ALT≤1×ULN亚组未见。
要点
- ALT 1–2×ULN的非肝硬化CHB患者接受NA治疗可显著降低肝癌和肝硬化风险
- ALT≤1×ULN亚组未见一致获益,支持将治疗门槛扩展至轻度ALT升高人群
- 经IPTW和PSM双重验证,NA治疗与肝癌风险aHR 0.14、肝硬化aHR 0.30相关
核心结论
- 核苷(酸)类似物治疗可降低ALT轻度升高(1–2×ULN)的非肝硬化慢性乙肝患者的肝癌和肝硬化风险。
研究设计与样本
- 回顾性多中心研究,纳入3734例ALT<2×ULN的非肝硬化慢性乙肝患者,采用IPTW和PSM平衡组间基线特征。
主要发现
- 37.8%患者接受NA治疗;IPTW后治疗组5年肝癌累积发生率0.9% vs 未治疗组4.4%(P<.001),肝硬化4.0% vs 8.9%(P<.001)。
- 多因素Cox分析中NA治疗与肝癌风险降低相关(aHR 0.14;95%CI 0.05–0.37;P<.001),与肝硬化风险降低相关(aHR 0.30;95%CI 0.18–0.50;P<.001)。
- 上述结果在ALT 1–2×ULN亚组中一致,但在ALT≤1×ULN亚组中不一致;PSM队列结果相似。
关键数值与推荐
- 研究人群界定为ALT<2×ULN的非肝硬化CHB患者;获益亚组为ALT 1–2×ULN。
- NA治疗组5年肝癌累积发生率0.9%、肝硬化4.0%;未治疗组分别为4.4%和8.9%。
临床怎么用
- 对ALT处于1–2×ULN的非肝硬化CHB患者,可考虑启动NA抗病毒治疗以降低远期肝癌和肝硬化风险。
- 研究结果支持扩展抗病毒治疗指征,对此类患者进行早期治疗。
局限性
- 为回顾性研究设计,可能存在残余混杂。
- ALT≤1×ULN亚组未观察到一致获益,结论主要适用于ALT 1–2×ULN人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The long-term benefit of antiviral treatment with nucleos(t)ide analogues (NAs) for non-cirrhotic patients with chronic hepatitis B (CHB) without significant alanine aminotransferase (ALT) elevation remains debatable. We investigated the impact of NA treatment on the long-term risk of hepatocellular carcinoma (HCC) and cirrhosis in these patients. METHODS: This retrospective multicenter study included 3734 non-cirrhotic patients with CHB with ALT <2 × the upper limit of normal (ULN). To balance baseline characteristics between treated and untreated patients, inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were applied. The risk of HCC and cirrhosis development was compared between the treated and untreated patients. RESULTS: Of all patients, 37.8% received NA treatment. After IPTW, treated patients had a significantly lower 5-year cumulative incidence of HCC (0.9% vs 4.4%; P < .001) and cirrhosis (4.0% vs 8.9%; P < .001) than untreated patients. In multivariate Cox analyses, NA therapy was associated with a significantly lower risk of developing HCC (adjusted hazard ratio [aHR], 0.14; 95% confidence interval [CI], 0.05-0.37; P < .001) and cirrhosis (aHR, 0.30; 95% CI, 0.18-0.50; P < .001) in the IPTW cohort. The findings were consistent in the subgroup of patients with ALT 1 to 2 × ULN but not in those with ALT ≤1 × ULN. Similar results were obtained in the PSM cohort. CONCLUSIONS: NA therapy reduced the risk of HCC and cirrhosis in non-cirrhotic CHB patients with mildly elevated ALT levels (1-2 × ULN). These findings support the expansion of antiviral treatment criteria for the early treatment of these patients.
引用
- Wang J, Zhang Z, Zhu L, et al. Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase. Clin Gastroenterol Hepatol. 2026. PMID: 41713830. doi:10.1016/j.cgh.2026.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。